MorphoSys files for $150M IPO to fuel its hopeful DLBCL drug launch
MorphoSys, a public company in Germany, is shooting for a dual listing of its shares, hoping to raise $150 million by heading to the Nasdaq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.